{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:15:24Z","timestamp":1776921324946,"version":"3.51.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Taishan Scholars","award":["No.tsqn202103146"],"award-info":[{"award-number":["No.tsqn202103146"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070392"],"award-info":[{"award-number":["82070392"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-05173-x","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:53:35Z","timestamp":1767106415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of new tetralogy drugs on ventricular remodeling in heart failure patients: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Xi-Wen","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gan-Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Nan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Yuan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"12","key":"5173_CR1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.cardfail.2017.09.014","volume":"23","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang J, Butler J, Yang X, Xie P, Guo D, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China heart failure (China-HF) registry. J Card Fail. 2017;23(12):868\u201375.","journal-title":"J Card Fail"},{"issue":"1","key":"5173_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/j.2040-4603.2016.tb00669.x","volume":"6","author":"E Tanai","year":"2015","unstructured":"Tanai E, Frantz S. Pathophysiology of heart failure. Compr Physiol. 2015;6(1):187\u2013214.","journal-title":"Compr Physiol"},{"issue":"5","key":"5173_CR3","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/0002-9149(82)90035-2","volume":"49","author":"JA Erlebacher","year":"1982","unstructured":"Erlebacher JA, Weiss JL, Eaton LW, Kallman C, Weisfeldt ML, Bulkley BH. Late effects of acute infarct dilation on heart size: a two dimensional echocardiographic study. Am J Cardiol. 1982;49(5):1120\u20136.","journal-title":"Am J Cardiol"},{"issue":"4","key":"5173_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1161\/01.CIR.74.4.693","volume":"74","author":"RG McKay","year":"1986","unstructured":"McKay RG, Pfeffer MA, Pasternak RC, Markis JE, Come PC, Nakao S, et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation. 1986;74(4):693\u2013702.","journal-title":"Circulation"},{"issue":"4","key":"5173_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation. 2021;143(4):326\u201336.","journal-title":"Circulation"},{"issue":"6","key":"5173_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516\u201325.","journal-title":"Circulation"},{"issue":"6","key":"5173_CR7","doi-asserted-by":"publisher","first-page":"820","DOI":"10.7326\/M21-4776","volume":"175","author":"JH Butt","year":"2022","unstructured":"Butt JH, Dewan P, Merkely B, Belohl\u00e1vek J, Dro\u017cd\u017c J, Kitakaze M, et al. Efficacy and safety of Dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial. Ann Intern Med. 2022;175(6):820\u201330.","journal-title":"Ann Intern Med"},{"issue":"6","key":"5173_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamacardio.2021.0379","volume":"6","author":"JH Butt","year":"2021","unstructured":"Butt JH, Docherty KF, Petrie MC, Schou M, Kosiborod MN, O\u2019Meara E, et al. Efficacy and safety of Dapagliflozin in men and women with heart failure with reduced ejection fraction: a prespecified analysis of the Dapagliflozin and prevention of adverse outcomes in heart failure trial. JAMA Cardiol. 2021;6(6):678\u201389.","journal-title":"JAMA Cardiol"},{"issue":"44","key":"5173_CR9","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","volume":"38","author":"RE Schmieder","year":"2017","unstructured":"Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, et al. The effect of sacubitril\/valsartan compared to Olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38(44):3308\u201317.","journal-title":"Eur Heart J"},{"issue":"10","key":"5173_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cardfail.2016.03.017","volume":"22","author":"A Jaiswal","year":"2016","unstructured":"Jaiswal A, Nguyen VQ, Carry BJ, le Jemtel TH. Pharmacologic and endovascular reversal of left ventricular remodeling. J Card Fail. 2016;22(10):829\u201339.","journal-title":"J Card Fail"},{"issue":"5","key":"5173_CR11","first-page":"740","volume":"7","author":"AM Shah","year":"2014","unstructured":"Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O\u2019Meara E, et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation: Heart Failure. 2014;7(5):740\u201351.","journal-title":"Circulation: Heart Failure"},{"issue":"27","key":"5173_CR12","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1093\/eurheartj\/ehac223","volume":"43","author":"S Frantz","year":"2022","unstructured":"Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J. 2022;43(27):2549\u201361.","journal-title":"Eur Heart J"},{"issue":"6","key":"5173_CR13","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1002\/ehf2.13645","volume":"8","author":"NK Dhingra","year":"2021","unstructured":"Dhingra NK, Mistry N, Puar P, Verma R, Anker S, Mazer CD, et al. SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials. ESC Heart Fail. 2021;8(6):4693\u2013700.","journal-title":"ESC Heart Fail"},{"issue":"5","key":"5173_CR14","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/S0735-1097(97)00012-0","volume":"29","author":"RN Doughty","year":"1997","unstructured":"Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand heart failure research collaborative group. J Am Coll Cardiol. 1997;29(5):1060\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"5173_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"7","key":"5173_CR16","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"7","key":"5173_CR17","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/hrt.2003.015552","volume":"90","author":"NG Bellenger","year":"2004","unstructured":"Bellenger NG, Rajappan K, Rahman SL, Lahiri A, Raval U, Webster J, et al. Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart. 2004;90(7):760\u20134.","journal-title":"Heart"},{"issue":"4","key":"5173_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ejheart.2004.10.015","volume":"7","author":"I Edes","year":"2005","unstructured":"Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail. 2005;7(4):631\u20139.","journal-title":"Eur J Heart Fail"},{"key":"5173_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ahj.2022.04.008","volume":"250","author":"J Jensen","year":"2022","unstructured":"Jensen J, Omar M, Ali M, Frederiksen PH, Kistorp C, Tuxen C, et al. The effect of empagliflozin on contractile reserve in heart failure: prespecified sub-study of a randomized, double-blind, and placebo-controlled trial. Am Heart J. 2022;250:57\u201365.","journal-title":"Am Heart J"},{"issue":"2","key":"5173_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/01.CIR.86.2.431","volume":"86","author":"MA Konstam","year":"1992","unstructured":"Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitor Enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators Circulation. 1992;86(2):431\u20138.","journal-title":"SOLVD Investigators Circulation"},{"issue":"7","key":"5173_CR21","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","volume":"6","author":"M Omar","year":"2021","unstructured":"Omar M, Jensen J, Ali M, Frederiksen PH, Kistorp C, Videb\u00e6k L, et al. Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the Empire HF randomized clinical trial. JAMA Cardiol. 2021;6(7):836\u201340.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"5173_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0167-4943(99)00040-0","volume":"29","author":"R Leonetti Luparini","year":"1999","unstructured":"Leonetti Luparini R, Celli V, Piccirillo G, Guidi V, Cacciafesta M, Marigliano V. Carvedilol in elderly patients with chronic heart failure, a 12 weeks randomized, placebo controlled open trial. Arch Gerontol Geriatr. 1999;29(3):275\u201382.","journal-title":"Arch Gerontol Geriatr"},{"issue":"17","key":"5173_CR23","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","volume":"76","author":"CS Barr","year":"1995","unstructured":"Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76(17):1259\u201365.","journal-title":"Am J Cardiol"},{"issue":"12","key":"5173_CR24","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1161\/CIRCHEARTFAILURE.121.008837","volume":"14","author":"JH Butt","year":"2021","unstructured":"Butt JH, Adamson C, Docherty KF, de Boer RA, Petrie MC, Inzucchi SE, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circ Heart Fail. 2021;14(12):1305\u201318.","journal-title":"Circ Heart Fail"},{"issue":"21","key":"5173_CR25","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"18","key":"5173_CR26","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140(18):1463\u201376.","journal-title":"Circulation"},{"issue":"15","key":"5173_CR27","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"6","key":"5173_CR28","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1388-9842(02)00114-9","volume":"4","author":"A Palazzuoli","year":"2002","unstructured":"Palazzuoli A, Bruni F, Puccetti L, Pastorelli M, Angori P, Pasqui AL, et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail. 2002;4(6):765\u201370.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"5173_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1161\/01.CIR.88.2.481","volume":"88","author":"H Pouleur","year":"1993","unstructured":"Pouleur H, Rousseau MF, van Eyll C, Stoleru L, Hayashida W, Udelson JA, et al. Effects of long-term Enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. SOLVD Investigators Circulation. 1993;88(2):481\u201391.","journal-title":"SOLVD Investigators Circulation"},{"issue":"4","key":"5173_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10557-008-6099-6","volume":"22","author":"J Rosenberg","year":"2008","unstructured":"Rosenberg J, Gustafsson F, Remme WJ, Riegger GA, Hildebrandt PR. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. Cardiovasc Drugs Ther. 2008;22(4):305\u201311.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"5173_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"5173_CR32","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.122.059210","volume":"146","author":"AM Shah","year":"2022","unstructured":"Shah AM, Claggett B, Prasad N, Li G, Volquez M, Jering K, et al. Impact of sacubitril\/valsartan compared with ramipril on cardiac structure and function after acute myocardial infarction: the PARADISE-MI echocardiographic substudy. Circulation. 2022;146(14):1067\u201381.","journal-title":"Circulation"},{"issue":"5","key":"5173_CR33","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","volume":"37","author":"T Tsutamoto","year":"2001","unstructured":"Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37(5):1228\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"5173_CR34","first-page":"347","volume":"3","author":"JE Udelson","year":"2010","unstructured":"Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA, et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circulation: Heart Failure. 2010;3(3):347\u201353.","journal-title":"Circulation: Heart Failure"},{"issue":"9","key":"5173_CR35","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.amjcard.2010.06.052","volume":"106","author":"E Vizzardi","year":"2010","unstructured":"Vizzardi E, D\u2019Aloia A, Giubbini R, Bordonali T, Bugatti S, Pezzali N, et al. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol. 2010;106(9):1292\u20136.","journal-title":"Am J Cardiol"},{"key":"5173_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","volume":"228","author":"J Jensen","year":"2020","unstructured":"Jensen J, Omar M, Kistorp C, Poulsen MK, Tuxen C, Gustafsson I, et al. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial. Am Heart J. 2020;228:47\u201356.","journal-title":"Am Heart J"},{"issue":"2","key":"5173_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ejhf.3129","volume":"26","author":"MS Usman","year":"2024","unstructured":"Usman MS, Januzzi JL, Anker SD, Salman A, Parikh PB, Adamo M, et al. The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: systematic review and meta-analysis. Eur J Heart Fail. 2024;26(2):373\u201382.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"5173_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/17512433.2023.2173574","volume":"16","author":"M Velliou","year":"2023","unstructured":"Velliou M, Polyzogopoulou E, Ventoulis I, Parissis J. Clinical pharmacology of SGLT-2 inhibitors in heart failure. Expert Rev Clin Pharmacol. 2023;16(2):149\u201360.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"5173_CR39","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","volume":"9","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2021","unstructured":"Requena-Ib\u00e1\u00f1ez JA, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Mancini D, Sartori S, et al. Mechanistic insights of empagliflozin in nondiabetic patients with hfref: from the EMPA-TROPISM study. JACC Heart Fail. 2021;9(8):578\u201389.","journal-title":"JACC Heart Fail"},{"issue":"3","key":"5173_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60030395","volume":"60","author":"K Katogiannis","year":"2024","unstructured":"Katogiannis K, Thymis J, Kousathana F, Pavlidis G, Korakas E, Kountouri A, et al. Effects of liraglutide, empagliflozin and their combination on left atrial strain and arterial function. Medicina (Kaunas, Lithuania). 2024;60(3):395.","journal-title":"Medicina (Kaunas, Lithuania)"},{"issue":"18","key":"5173_CR41","first-page":"e876","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e876-94.","journal-title":"Circulation"},{"issue":"37","key":"5173_CR42","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"issue":"7387","key":"5173_CR43","first-page":"472","volume":"326","author":"F Song","year":"2003","unstructured":"Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ (Clinical Res ed). 2003;326(7387):472.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"4","key":"5173_CR44","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v17.i4.104717","volume":"17","author":"R Parizad","year":"2025","unstructured":"Parizad R, Batta A, Hatwal J, Taban-Sadeghi M, Mohan B. Emerging risk factors for heart failure in younger populations: a growing public health concern. World J Cardiol. 2025;17(4):104717.","journal-title":"World J Cardiol"},{"issue":"1","key":"5173_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-025-05036-5","volume":"25","author":"S Rani","year":"2025","unstructured":"Rani S, Kumar L, Ali SME, Ashraf S, Bhimani S, Kumar S, et al. Trends in United States mortality among patients with atrial fibrillation\/flutter related heart failure (1999\u20132024): disparities by gender, race\/ethnicity and region. BMC Cardiovasc Disord. 2025;25(1):558.","journal-title":"BMC Cardiovasc Disord"},{"key":"5173_CR46","volume-title":"Trends and projections of heart failure among adolescents and young adults: an in-depth analysis for the Global Burden of Disease Study 2021","author":"S Shu","year":"2025","unstructured":"Shu S, Zeng Z, Yang Y, Wang H, Sun B, Thangaraju P, et al. Trends and projections of heart failure among adolescents and young adults: an in-depth analysis for the Global Burden of Disease Study 2021. European heart journal Quality of care & clinical outcomes; 2025."}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05173-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05173-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05173-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:04:03Z","timestamp":1767150243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-025-05173-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5173"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05173-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"906"}}